Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEunice MagalhãesSKSteven M. Kornblau

Discussion

Loading...

Member takes

Overview

Analysis reveals low JAK2 expression worsens outcomes in acute myelogenous leukemia, implying importance of therapy alignment.

Key Points

  • Low expression of JAK2 results in worse overall survival, independent of treatment.
  • Patients with JAK2V617F mutation have significantly lower response rates compared to wild-type, underscoring the importance of protein levels for prognosis.
  • Differential expression analysis highlights the relevance of JAK2 in assessing leukemogenesis and patient outcomes in acute myelogenous leukemia.
  • Proteomics can aid in triaging patients based on JAK2 levels, potentially guiding more effective therapies.

Cite This Study

Magalhães et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236d9f4https://doi.org/10.1182/blood-2025-3494
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  2. 2Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.2025
  3. 3Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia2025
  4. 4High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  5. 5Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status2025